21-24 September 2024
European College of Neuropsychopharmacology (ECNP) congress 2024
Allianz MiCo convention center, Milan
MI
Italy
Oral presentation: Friday September 23rd 2024
Title: “Final Results: PORTICO a double-blind, randomized placebo-controlled, adaptive phase IIb trial to assess vafidemstat’s efficacy in treating borderline personality disorder”
Presenter: Dr Michael Ropacki, Oryzon’s Chief Medical Officer for CNS